immunity News and Research

RSS

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

New research has been published in The Lancet Respiratory Medicine, which focuses on evaluating the effect of SARS-CoV-2 seropositivity on the possibility of developing SARS-CoV-2 infection in a young and healthy population. This study is based on the longitudinal prospective cohort study that involves the COVID-19 Health Action Response for Marines (CHARM).

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

A recent review in the International Journal of Biological Macromolecules provides a novel overview of 'virosome'-based nanovaccine production, its properties, and its application in viral diseases, emphasizing its importance in SARS-CoV-2 vaccine discovery.

20 Apr 2021

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study published in Frontiers in Immunology.

20 Apr 2021

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Opioid addicts wage a daily war within over whether or not to use a drug whose side effect can be death. If those same addicts, however, had the choice to take an opioid vaccine once or twice a year, their internal struggle could be over.

20 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Majority of Americans support COVID-19 vaccine mandates, study finds

As vaccines that help protect against COVID-19 become available for more people across the United States, questions have been raised about whether institutions like schools and universities should require their students and staff to become vaccinated.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Could a tuna-derived protein inhibit SARS-CoV-2?

A recent study in the journal Food Chemistry draws attention to the need for finding nutritional supplements with potential SARS-CoV-2 inhibition effects in the wake of the COVID-19 pandemic.

19 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

The shock and reality of catching Covid after being vaccinated

Robin Hauser, a pediatrician in Tampa, Fla., got covid in February. What separates her from the vast majority of the tens of millions of other Americans who have come down with the virus is this: She got sick seven weeks after her second dose of the Pfizer-BioNTech vaccine.

17 Apr 2021

Ask KHN-Politifact: I’ve recovered from Covid. Why do i still have to mask up?

More than 120 million Americans have joined arguably the most sought-after club on Earth: those immunized against the coronavirus.

16 Apr 2021

Researchers identify risk factors for SARS-CoV-2 reinfection

A team of scientists from the Capital Medical University and Peking University, China, has recently explored the factors responsible for the reactivation of SARS-CoV-2 infection among individuals who have recently recovered from COVID-19. The findings reveal that individuals with lower lymphocyte count or with two or fewer symptoms during the first COVID-19 episode are at higher risk of recurrent infection.

16 Apr 2021

Rapid mRNA vaccination effectively controls SARS-CoV-2 transmission in long-term care facilities

Vaccine rollouts all over the world are aimed at cutting short the coronavirus disease 2019 (COVID-19) pandemic by inducing antibody-mediated immunity to the virus. A new study, recently released on the medRxiv* preprint server, addresses the successful reduction in viral spread and case incidence among residents of long-term care facilities (LTCF).

16 Apr 2021

Recovered COVID-19 patients may need only a single vaccine dose, suggests study

People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published today in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.

16 Apr 2021

Cell receptor neuropilin-1 offers a promising anti-tumor strategy

Cancer is an insidious disease that, despite being around for centuries, is still very difficult to diagnose and treat. Thus, cancer has been the focus much research in the biomedical fields.

16 Apr 2021

Study reveals new genes that program stem cells to make dendritic cells

Using a new single-cell technique, WEHI researchers have uncovered a way to understand the programming behind how stem cells make particular cell types.

16 Apr 2021

More SARS-CoV-2 variants have emerged from immunocompromised hosts, shows research

A number of SARS-CoV-2 variants have emerged from immunocompromised hosts, research has identified. It is thought that variants of concern - including B.1.1.7, a variant first identified in Kent - were a result of long-term infection in people with a weakened immune system.

16 Apr 2021

Study: Previous COVID-19 infection does not completely protect against reinfection in young people

A past COVID-19 infection does not completely protect against reinfection in young people, according to an observational study of more than 3,000 healthy members of the US Marines Corps most of whom were aged 18-20 years, published in The Lancet Respiratory Medicine journal.

16 Apr 2021

immunity News and Research

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Could virosome-based nanovaccines be a promising new approach to preventing viral diseases?

Gut's immune response in COVID-19 patients may not provide adequate protection to other organs

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Majority of Americans support COVID-19 vaccine mandates, study finds

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Could a tuna-derived protein inhibit SARS-CoV-2?

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

The shock and reality of catching Covid after being vaccinated

Ask KHN-Politifact: I’ve recovered from Covid. Why do i still have to mask up?

Researchers identify risk factors for SARS-CoV-2 reinfection

Rapid mRNA vaccination effectively controls SARS-CoV-2 transmission in long-term care facilities

Recovered COVID-19 patients may need only a single vaccine dose, suggests study

Cell receptor neuropilin-1 offers a promising anti-tumor strategy

Study reveals new genes that program stem cells to make dendritic cells

More SARS-CoV-2 variants have emerged from immunocompromised hosts, shows research

Study: Previous COVID-19 infection does not completely protect against reinfection in young people

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News